Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Lynda M. O'Riordan"'
Autor:
Lynda M. O'Riordan, Michael Thomas McCarthy, John McCaffrey, Jane Sze Yin Sui, Deirdre Kelly, Saira Nasim, Cliona O'Donnell, MinYuen Teo, John Patrick Buckley, Sarah Louise Picardo
Publikováno v:
Journal of Clinical Oncology. 33:e15549-e15549
e15549 Background: Clinical stage one testicular seminoma has a survival rate over 99%. Current guidelines recommend Active Surveillance as the mainstay of treatment. The present analysis aims to i...
Autor:
Saira Nasim, M. Higgins, Sarah Louise Picardo, Michael Thomas McCarthy, Desmond N. Carney, Deirdre Kelly, MinYuen Teo, John McCaffrey, Catherine M. Kelly, Jane Sze Yin Sui, Lynda M. O'Riordan
Publikováno v:
Journal of Clinical Oncology. 33:e11540-e11540
e11540 Background: Breast cancer is the most commonly diagnosed malignancy in women. Due to widespread use of mammographic screening and awareness campaigns, under 10% present with metastatic disea...
Autor:
Sarah Louise Picardo, MinYuen Teo, John McCaffrey, Deirdre Kelly, Michael Thomas McCarthy, Lynda M. O'Riordan, Jacklyn Sze Tin Sui, Jane Sze Yin Sui
Publikováno v:
Journal of Clinical Oncology. 33:e20519-e20519
e20519 Background: The incidence of cancer is expected to rise significantly with aging population. Historically, clinical trials were less likely to enrol older patients (pts) out of concerns for ...
Autor:
John McCaffrey, Cliona O'Donnell, Michael Thomas McCarthy, Jane Sze Yin Sui, MinYuen Teo, Lynda M. O'Riordan, Sarah Louise Picardo, Deirdre Kelly
Publikováno v:
Journal of Clinical Oncology. 33:e14683-e14683
e14683 Background: Colorectal cancer remains a significant cause of cancer related mortality worldwide. KRAS status has been used as a negative predictive marker. Its effect on the natural history ...
Autor:
Megan Greally, William Grogan, Michelle O'Brien, Lynda M. O'Riordan, Oscar S. Breathnach, Niamh Coleman, Karen Anne Cadoo
Publikováno v:
Journal of Clinical Oncology. 31:e13019-e13019
e13019 Background: High grade gliomas(HGG) are aggressive primary brain tumors. Most patients relapse following adjuvant therapy and treatment options are limited. Novel therapies have impacted little on overall survival (OS). Bevacizumab is approved
Autor:
Niamh Coleman, Megan Greally, Oscar S. Breathnach, Bryan T. Hennessy, Lynda M. O'Riordan, Christopher J. Thompson, William Grogan
Publikováno v:
Journal of Clinical Oncology. 31:e13022-e13022
e13022 Background: ACTH-producing pituitary carcinomas (APPC) are malignant neuroendocrine tumors affecting the adenohypophysis. They are extremely rare, with a poor prognosis. They are poorly responsive to chemotherapy and radiotherapy. We report th